Selective optimization of side activities: The SOSA approach

Drug Discovery Today

Volumn 11, Issue 3-4, 2006, Pages 160-164

  Wermuth, Camille G ^a  

^a Prestwick Chemical Inc   (France)

Author keywords

[No Author keywords available]

Indexed keywords

5 DIMETHYLAMINO N (3,4 DIMETHYL 5 ISOXAZOLYL) 1 NAPHTHALENESULFONAMIDE; AMILORIDE; ATENOLOL; BAZINAPRINE; BMS 193884; BMS 207940; DIAZEPAM; DICLOFENAC; ERYTHROMYCIN; FLUOXETINE; MINAPRINE; NIGULDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDAZINE DERIVATIVE; SULFAFURAZOLE; SULFATHIAZOLE; SULFONAMIDE; SULPIRIDE; TETRACYCLINE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIHYPERTENSIVE ACTIVITY; BINDING AFFINITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HEMODYNAMICS; HUMAN; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION; UNSPECIFIED SIDE EFFECT;

BIOLOGICAL AVAILABILITY; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; STRUCTURE-ACTIVITY RELATIONSHIP; TOXICOLOGY;

EID: 33644858616     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(05)03686-X     Document Type: Review

References (45)

1. T.N.K. Raju Nobel chronicles The Lancet 355 2000 1022 1024
2. Sternbach L.H. The benzodiazepine story J. Med. Chem. 22 1979 1 7
3. C.G. Wermuth Search for new lead compounds: the example of the chemical and pharmacological dissection of aminopyridazines J. Heterocyclic Chem. 35 1998 1091 1100
4. C.G. Wermuth, Clarence-Smith K. Drug-like leads: bigger is not always better Pharmaceutical News 7 2000 53 57
5. C.G. Wermuth The SOSA approach: an alternative to high-throughput screening Med. Chem. Res. 10 2001 431 439
6. C.G. Wermuth Strategies in the search for new lead compounds or original working hypotheses Wermuth C.G. The Practice of Medicinal Chemistry 2nd edn 2003 Academic Press 69 89
7. C.G. Wermuth Selective optimization of side activities: another way for drug discovery J. Med. Chem. 47 2004 1303 1314
8. C.G. Wermuth, Exinger A. Le dichlorhydrate de la morpholinoé thylamino-3 méthyl-4 phényl-6 pyridazine (Agric. 1240) Agressologie 13 1972 285 289
9. C.G. Wermuth 3-Aminopyridazine derivatives with atypical antidepressant, serotonergic and dopaminergic activities J. Med. Chem. 32 1989 528 537
10. H. Laborit Etude biochimique et pharmacologique du 3-(2- morpholino-éthylamino) 4-méthyl 6-phényl pyridazine dichlorhydrate (Agric. 1240) Agressologie 13 1972 291 318
11. K. Bizière Pharmacological evaluation of minaprine dihydrochloride, a new psychotropic drug. Arzneim.-Forsch. Drug Res. 32 1982 824 831
12. P. Worms Profil pharmacologique d'un psychotrope original, la minaprine: comparaison avec six antidépresseurs de référence J. Pharmacol. Exptl. Therap. 17 1986 126 138
13. P. Worms Dopamine-like activities of an aminopyridazine derivative, CM 30366: a behavioural study Naunyn Schmiedebergs Arch. Pharmacol. 334 1986 246 252
14. 14C]minaprine in man Xenobiotica 11 1981 735 747
15. P. Worms SR 95191 a selective inhibitor of type A monoamine oxidase with dopaminergic properties. I. Psychopharmacological profile in rodents J. Pharmacol. Exp. Ther. 240 1987 241 250
16. S. Garattini Neurochemical effects of minaprine, a novel psychotropic drug, on the central cholinergic system of the rat Psychopharmacology (Berl.) 82 1984 210 214
17. M. Passeri Comparison of minaprine and placebo in the treatment of Alzheimer's disease and multi-infarct dementia Int. J. Geriatr. Psychiatry 2 1987 97 103
18. C.G. Wermuth SR 46559 A and related aminopyridazines are potent muscarinic agonists with no cholinergic syndrome Bioorg. Med. Chem. Lett. 2 1992 833 838
19. J-P. Kan SR 46559A: a novel and potent muscarinic compound with no cholinergic syndrome Psychopharmacology (Berl.) 112 1993 219 227
20. Contreras J-M. Aminopyridazines as acetylcholinesterase inhibitors J. Med. Chem. 42 1999 730 741
21. Contreras J-M. Design, synthesis and structure-activity relationships of a series of 3-[2-(1- benzylpiperidin-4-yl)ethylamino]pyridazine derivatives as acetylcholinesterase inhibitors J. Med. Chem. 44 2001 2707 2718
22. A antagonist 5-(dimethylamino)-N- (3,4-dimethyl-5-isoxazoly1)-l-naphthalenesulfonamide J. Med. Chem. 37 1994 329 331
23. A selective antagonist J. Med. Chem. 46 2003 125 137
24. P.W. Baures Discovering transthyretin amyloid fibril inhibitors by limited screening Bioorg. Med. Chem. 6 1998 1389 1401
25. V.B. Oza Synthesis, structure and activity of diclofenac analogues as transthyretin amyloid fibril formation inhibitors J. Med. Chem. 45 2002 321 332
26. Lipinski C.A. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Deliv. Rev. 46 2001 3 26
27. D.F. Veber Molecular properties that influence the oral bioavailability of drug candidates J. Med. Chem. 45 2002 2615 2623
28. Bergström C.A.S. Absorption classification of oral drugs based on molecular surface properties J. Med. Chem. 46 2003 558 570
29. M.C. Wenlock A comparison of physicochemical property profiles of development and marketed oral drugs J. Med. Chem. 46 2003 1250 1256
30. C. Burnouf Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4] diazepino[6,7,1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitors J. Med. Chem. 43 2000 4850 4867
31. Randolph J.T. Nonpeptide luteinizing hormone-releasing hormone antagonists derived from erythromycin A: design, synthesis, and biological activity of cladinose replacement analogues J. Med. Chem. 47 2004 1085 1097
32. A. Fura Discovering drugs through biological transformation: role of pharmacologically active metabolites in drug discovery J. Med. Chem. 47 2004 4339 4351
33. Proudfoot J.R. Drugs, leads, and drug-likeness: an analysis of some recently launched drugs Bioorg. Med. Chem. Lett. 12 2002 1647 1650
34. T.I. Oprea Is there a difference between leads and drugs? A historical perspective J. Chem. Inf. Comput. Sci. 41 2001 1308 1315
35. + exchanger Drugs 2 1999 1009 1025
36. B. Lagu Identification of 1A-adrenoceptor selective antagonists for the treatment of benign prostatic hyperplasia Drugs Fut. 26 2001 757 765
37. Ks channel blockers: potential antiarrhythmic agents Drugs Fut. 26 2001 473 484
38. D. Gully Elf-Sanofi, Dérivés alkylamino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent French Demande 1992 N°9207736
39. D. Gully Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor Proc. Natl. Acad. Sci. U. S. A. 90 1993 65 69
40. D. Gully Sanofi, 4-Phenyl-aminothiazole derivatives, method for preparing same and pharmaceutical compositions containing said derivatives World Patent 1997 WO9700868
41. 3 agonist Nature 400 1999 371 375
42. 3 Actual. Chim. 2003 91 94
43. H. Riechers Discovery and optimization of a novel class of orally active non-peptidic endothelin-A receptor antagonists J. Med. Chem. 39 1996 2123 2128
44. Y.Z. Shu BMS-192548, a tetracyclic binding inhibitor of neuropeptide Y receptors, from Aspergillus niger WB2346. II. Physico-chemical properties and structural characterization J. Antibiot. (Tokyo) 48 1995 1060 1065
45. R. Silvestri Imidazole analogues of fluoxetine, a novel class of anti-candida agents J. Med. Chem. 47 2004 3924 3926